HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories Ltd. has announced the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the first to market in the U.S. as a generic equivalent of Extra-Strength Pataday Once-Daily Relief, following FDA approval.
The antihistamine eye drop is designed for temporary relief of itchy eyes caused by allergens like pollen, ragweed, grass, animal hair, and dander. The product comes in a 2.5-mL bottle and expands Dr. Reddy’s OTC eye-care lineup, which already includes olopatadine solutions at 0.2% and 0.1% strengths.
“This launch adds to our current portfolio in the OTC eye-care space,” said Milan Kalawadia, CEO, North America Generics, Dr. Reddy’s Laboratories Inc. “The first-to-market launch underscores our capabilities in bringing store-brand equivalents of leading OTC brands to the U.S. market, and we look forward to deepening collaboration with our retail partners.”
According to NielsenIQ (NIQ) data, the Pataday brand generated approximately $69.9 million in U.S. sales during the latest 52-week period ending December 27, 2025.* Pataday is a registered trademark of Novartis AG.
Dr. Reddy’s stated that the launch aligns with its broader strategy to expand access to affordable OTC therapies while supporting retailer store-brand programs across key self-care categories.
*NielsenIQ Retail Measurement, xAOC, data through December 2025
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
